Clinical trial • Phase I/II • Oncology
Clinical trial in Triple negative breast cancer
Phase I/II trial for Triple negative breast cancer. Placebo control group (details not specified). 50 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Triple negative breast cancer
- Trial Stage
- Phase I/II
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 27-04-2024
- First CTIS Authorization Date
- 29-07-2024
Trial design
Placebo control group (details not specified) Phase I/II trial across 1 site in Slovenia.
- Comparator
- Placebo control group (details not specified)
- Target Sample Size
- 50
Recruitment
- Planned Sample Size
- 50
- Recruitment Window Months
- 47
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 50
Slovenia
- Earliest CTIS Part Ii Submission Date
- 02-07-2024
- Latest Decision Or Authorization Date
- 29-07-2024
- Processing Time Days
- 27
- Number Of Sites
- 1
- Number Of Participants
- 50
Sites
- Site Name
- Institute Of Oncology Ljubljana
- Department Name
- Sektor internistične onkologije
- Contact Person Name
- Simona Borštnar
- Contact Person Email
- SBorstnar@onko-i.si
- Number Of Participants
- 50
Sponsor
Primary sponsor
- Full Name
- Celica d.o.o.
- Organisation Type
- Laboratory/Research/Testing facility
- Country Of Registered Address
- Slovenia
Related trials
Other published trials that may interest you.